Posts

AbbVie's Skyrizi retakes edge in pharma's July ad spending league

AbbVie's Skyrizi retakes edge in pharma's July ad spending league. Skyrizi topped the list as the biggest pharma drug ad spender in July, with an estimated national TV ad spend of $23.2 million. Overall spending on TV drug ads fell sharply in July to $126.3 million from $163.2 million in June, marked by significant declines compared to earlier in the year. Skyrizi's dominance is part of a broader trend where AbbVie continues to lead the annual TV drug ad spending rankings, with Skyrizi as the top brand for the third consecutive year. Sources: AbbVie's Skyrizi, Rinvoq retake the top TV drug ad spenders' crown as top climber Rexulti continues strong run Skyrizi Tops July's Pharma Rankings — and What It Means for ... AbbVie's Skyrizi stays king of the drug ad spenders as total spending plummets July's Top Rx Brands by TV Ad Spend - The Measure TV drug ad spending plummeted in July, while AbbVie's Skyrizi regained ... Skyrizi soars to...

Eli Lilly’s Foundayo builds scripts after a disappointing Q2 amid oral GLP‑1 race with Novo Nordisk’s Wegovy pill

Sarepta delays Elevidys timeline amid FDA scrutiny

Tarsus Bets $450M on Alkeus Stargardt Drug in Up-to-$800M Deal

Replimune Melanoma Drug Snags Coveted FDA Approval After Yearlong Clash, Two Rejections

Greg Verdine's LifeMine raises $263M for safer immunosuppressant

Braveheart lands ~$383M IPO to take Hengrui cardio drug into Phase 3

Takeda Orzeyful ile ilk kez narkolepsi tip 1'in tüm belirtilerini kapsayan bir tedavi aldı.

Moderna's mRNA flu shot mFlusiva wins FDA nod after refusal‑to‑file controversy

Recent acquisitions of digestive health startups: Hinge Health, P&G, and others

AI-Designed First‑In‑Class Small Molecule Inhibitor Shows Promise Against Pancreatic Cancer in Preclinical Studies

Merger talks between AstraZeneca and Bristol Myers Squibb are off, report says

GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation